Pulmonx Corp represents a strong commitment to improving the lives of patients with severe lung diseases. Their corporate philosophy revolves around innovation, patient-centricity, and clinical excellence. The company values inclusivity, collaboration, and integrity in their pursuit of developing novel therapeutic solutions. Pulmonx Corp focuses on providing minimally invasive devices and technologies that offer better treatment options for conditions like chronic obstructive pulmonary disease (COPD) and emphysema. With a mission to enhance lung health, Pulmonx Corp continuously strives to advance medical knowledge, improve patient outcomes, and contribute to global respiratory innovation.

Pulmonx Corp is primarily present in various countries and regions around the world. These include the United States, Europe, Asia-Pacific, and Latin America.

Pulmonx Corp has achieved significant milestones in its journey. The company developed an innovative solution known as Zephyr Valve, which has revolutionized the treatment of severe emphysema. Pulmonx Corp received FDA approval for Zephyr Valve, making it the first minimally invasive implant to offer lung volume reduction in emphysema patients. This milestone marked a major breakthrough in the field of respiratory care. Additionally, Pulmonx Corp has expanded its global reach and established partnerships with renowned medical centers worldwide. These achievements highlight the company's commitment to improving the lives of patients suffering from debilitating lung diseases.

Pulmonx Corp is a leading medical technology company specializing in minimally invasive devices for patients suffering from severe lung diseases. Established in 1997, Pulmonx has dedicated its efforts to improving the lives of those with chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's innovative products, such as the Zephyr Valve System, offer a novel approach to lung disease treatment, providing patients with a non-surgical option that reduces hyperinflation and improves lung function. Pulmonx Corp has emerged as a global leader in the field, helping patients worldwide breathe easier and enhancing their quality of life.

The main competitors of Pulmonx Corp in the market are Boston Scientific Corporation and Olympus Corporation.

Pulmonx Corp is primarily active in the medical device industry.

The business model of Pulmonx Corp focuses on developing and commercializing minimally invasive medical devices for the treatment of severe respiratory diseases. The company specializes in creating novel solutions for conditions like emphysema and chronic bronchitis, offering patients and healthcare providers effective alternatives to traditional treatments. Pulmonx Corp's innovative technologies, such as the Zephyr Valve System, help improve lung function and quality of life for individuals suffering from severe respiratory conditions. With a strong emphasis on research, development, and collaboration, Pulmonx Corp strives to bring about advancements in respiratory care and provide targeted therapies for patients worldwide.

Pulmonx hissesinin F/K oranı -4,15.

Pulmonx KUV 3,29 dir.

Pulmonx için AlleAktien Kalite Skoru 4/10'dur.

beklenen Pulmonx cirosu 84,29 Milyon. USD dir.

beklenen Pulmonx karı -66,84 Milyon. USD olarak gerçekleşmiştir.

The company Pulmonx Corp is a leading manufacturer of medical devices that help patients with respiratory diseases. The company is headquartered in Redwood City, California and has branches all over the world. Pulmonx Corp's business model is based on the development, manufacturing, and marketing of products for the treatment of lung and respiratory diseases. There are several business areas that the company serves: 1. Endobronchial therapy Pulmonx Corp has developed a unique procedure for endobronchial therapy, in which a small implant is inserted into the trachea to open the airways. The procedure is particularly effective in patients with severe emphysema or chronic obstructive pulmonary disease (COPD). 2. Diagnostics The company also offers a wide range of diagnostic tests for respiratory diseases. These tests help doctors make the correct diagnosis and plan the best treatment for the patient. 3. Training and education Pulmonx Corp also operates an extensive training and education program for doctors and medical staff. The company offers a variety of workshops and training sessions for endobronchial therapy to ensure that doctors can use the technology safely and effectively. 4. Research and development An important part of Pulmonx's business model is the continuous research and development of new products and technologies for the treatment of respiratory diseases. The company invests significant resources in developing new implants for endobronchial therapy and researching new diagnostic tests. One example of a product offered by Pulmonx Corp is the Zephyr Valve. This is a small, implantable device that is placed in the patient's bronchi. The valve allows the patient to breathe more effectively by improving lung ventilation and expanding the airways. The valve is implanted using an endobronchial catheter and can usually be done on an outpatient basis. Most patients can go home the next day. Overall, Pulmonx Corp's business model has proven to be extremely successful. The company has carved out a unique niche in the respiratory technology market and is on its way to becoming a leading provider of endobronchial therapies and diagnostic tests. The company relies on scientifically based innovations to improve the health of people with respiratory diseases.

Pulmonx, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Pulmonx için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Pulmonx şirketinin ISIN kodu US7458481014’dir.

Pulmonx 'nin WKN'si A2P1AF 'dir.

Pulmonx için Ticker LUNG’dir.

Son 12 ay içerisinde Pulmonx, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Pulmonx, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Pulmonx şirketinin mevcut temettü verimi .

Pulmonx dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Pulmonx, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Pulmonx, 'Sağlık' sektörüne atanmıştır.

Son Pulmonx tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 04.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 04.10.2024 olarak gerçekleşti.

2023 yılında Pulmonx tarafından 0 USD olarak temettüler dağıtıldı.

Pulmonx hisselerinin temettüleri USD olarak dağıtılır.